PRICE T ROWE ASSOCIATES INC /MD/
Position in GALT — Galectin Therapeutics Inc
CIK 80255
BALTIMORE, MD
Position in GALT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$182,412
New position
Shares Held
39,313
first reported quarter
Ownership
0.039%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#41
of 98 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026PRICE T ROWE ASSOCIATES INC /MD/ holds $17,929,584,838 across 304 Biotechnology names. GALT ranks #257 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
2,678,047 | $2,484,611,664 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,529,709 | $953,834,749 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,728,421 | $858,558,562 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
|
7,112,980 | $815,645,416 | |
| 5 | RPRX |
Royalty Pharma plc
|
11,193,657 | $627,628,347 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
2,969,853 | $447,655,945 | |
| 7 | MRNA |
Moderna, Inc.
|
5,589,560 | $391,436,886 | |
| 8 | TWST |
Twist Bioscience Corp
|
3,634,652 | $373,932,997 |
All Filings in GALT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $182,412 | 39,313 | Shares | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||